Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. | Cancers (Basel) | 2023 | 37345056 | PubTator, text mining | PubMed |
| Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma. | Int J Gen Med | 2023 | 37342407 | PubTator, text mining | PubMed |
| Cis Interactions of Membrane Receptors and Ligands. | Annu Rev Cell Dev Biol | 2023 | 37339682 | PubTator, text mining | PubMed |
| Identifying the role of NUDCD1 in human tumors from clinical and molecular mechanisms: a study based on comprehensive bioinformatics and experimental validation. | Aging (Albany NY) | 2023 | 37338527 | PubTator, text mining | PubMed |
| A comprehensive analysis of FBN2 in bladder cancer: A risk factor and the tumour microenvironment influencer. | IET Syst Biol | 2023 | 37337404 | PubTator, text mining | PubMed |
| Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2. | Front Immunol | 2023 | 37334382 | PubTator, text mining | PubMed |
| An amino acid metabolism-based seventeen-gene signature correlates with the clinical outcome and immune features in pancreatic cancer. | Front Genet | 2023 | 37333498 | PubTator, text mining | PubMed |
| MIF promotes Th17 cell differentiation in Hashimoto's thyroiditis by binding HVEM and activating NF-κB signaling pathway. | Int Immunopharmacol | 2023 | 37331297 | PubTator, text mining | PubMed |
| A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma. | Cancer Med | 2023 | 37326144 | PubTator, text mining | PubMed |
| New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review). | Int J Oncol | 2023 | 37326100 | PubTator, text mining | PubMed |
| Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients. | Front Immunol | 2023 | 37325625 | PubTator, text mining | PubMed |
| Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells. | Front Cell Infect Microbiol | 2023 | 37325516 | PubTator, text mining | PubMed |
| T cell receptor and B cell receptor exhibit unique signatures in tumor and adjacent non-tumor tissues of hepatocellular carcinoma. | Front Immunol | 2023 | 37313417 | PubTator, text mining | PubMed |
| Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. | Cancer Cell | 2023 | 37311413 | PubTator, text mining | PubMed |
| Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression. | Front Med (Lausanne) | 2023 | 37305124 | PubTator, text mining | PubMed |
| Identification of immune-related genes and patient selection for hepatocellular carcinoma immunotherapy. | Transl Cancer Res | 2023 | 37304539 | PubTator, text mining | PubMed |
| Dissecting shared genetic architecture between obesity and multiple sclerosis. | EBioMedicine | 2023 | 37300932 | PubTator, text mining | PubMed |
| A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer. | J Cancer Res Clin Oncol | 2023 | 37291405 | PubTator, text mining | PubMed |
| Ex Vivo Infection of Human Skin Models with Herpes Simplex Virus 1: Accessibility of the Receptor Nectin-1 during Formation or Impairment of Epidermal Barriers Is Restricted by Tight Junctions. | J Virol | 2023 | 37289055 | PubTator, text mining | PubMed |
| Genomic and transcriptomic characterization reveals B-cell hyperactivation and immune evasion in hepatitis B virus-associated diffuse large B-cell lymphoma. | Clin Transl Med | 2023 | 37288581 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=27